Schizophrenia Research
Volume 120, Issue 1 , Pages 101-107 , July 2010

Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia

  • Serge Sevy

      Affiliations

    • The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Psychiatry Research, USA
    • Albert Einstein College of Medicine, Department of Psychiatry, USA
    • Corresponding Author InformationCorresponding author. Psychiatry Research, The Zucker Hillside Hospital, 75-59 263rd Street, Glen Oaks, NY 11004, USA. Tel.: +1 718 470 8175; fax: +1 718 343 1659.
    • ,
  • Delbert G. Robinson

      Affiliations

    • The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Psychiatry Research, USA
    • Albert Einstein College of Medicine, Department of Psychiatry, USA
    • Feinstein Institute for Medical Research, Center for Translational Psychiatry, USA
    • ,
  • Barbara Napolitano

      Affiliations

    • The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Psychiatry Research, USA
    • Feinstein Institute for Medical Research, Biostatistics Unit, USA
    • ,
  • Raman C. Patel

      Affiliations

    • Bronx Lebanon Hospital, Psychiatry Department, USA
    • ,
  • Handan Gunduz-Bruce

      Affiliations

    • Yale University School of Medicine, Psychiatry Department, USA
    • ,
  • Rachel Miller

      Affiliations

    • National Institute of Mental Health, USA
    • ,
  • Joanne McCormack

      Affiliations

    • The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Psychiatry Research, USA
    • ,
  • Beth S Lorell

      Affiliations

    • Bronx Lebanon Hospital, Psychiatry Department, USA
    • ,
  • John Kane

      Affiliations

    • The Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Psychiatry Research, USA
    • Albert Einstein College of Medicine, Department of Psychiatry, USA
    • Feinstein Institute for Medical Research, Center for Translational Psychiatry, USA

Received 15 January 2010 ,Revised 23 March 2010 ,Accepted 26 March 2010.

References 

  1. Addington J, Addington D. Impact of an early psychosis program on substance use. Psychiatry Rehabil. J. 2001;25(1):60–67
  2. Allebeck P, Adamsson C, Engstrom A, et al. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr. Scand. 1993;88(1):21–24
  3. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 1989;7:49–58
  4. Andreasson S, Allebeck P, Engstrom A, et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2(8574):1483–1486
  5. Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr. Scand. 1989;79(5):505–510
  6. Arndt S, Tyrrell G, Flaum M, et al. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol. Med. 1992;22(2):379–388
  7. Arseneault L, Cannon M, Poulton R, et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br. Med. J. 2002;325(7374):1212–1213
  8. Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 1989;154:672–676
  9. Barnes TR, Mutsatsa SH, Hutton SB, et al. Comorbid substance use and age at onset of schizophrenia. Br. J. Psychiatry. 2006;188:237–242
  10. Barnett JH, Werners U, Secher SM, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br. J. Psychiatry. 2007;190:515–520
  11. Basso MR, Nasrallah HA, Olson SC, et al. Cognitive deficits distinguish patients with adolescent- and adult-onset schizophrenia. Neuropsychiatry Neuropsychol. Behav. Neurol. 1997;10(2):107–112
  12. Bertelsen M, Jeppesen P, Petersen L, et al. Course of illness in a sample of 265 patients with first-episode psychosis — five-year follow-up of the Danish OPUS trial. Schizophr. Res. 2009;107(2–3):173–178
  13. Blanchard JJ, Brown SA, Horan WP, et al. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin. Psychol. Rev. 2000;20(2):207–234
  14. Breakey WR, Goodell H, Lorenz PC, et al. Hallucinogenic drugs as precipitants of schizophrenia. Psychol. Med. 1974;4(3):255–261
  15. Buhler B, Hambrecht M, Loffler W, et al. Precipitation and determination of the onset and course of schizophrenia by substance abuse — a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. 2002;54(3):243–251
  16. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982;8(3):470–484
  17. Cantwell R, Brewin J, Glazebrook C, et al. Prevalence of substance misuse in first-episode psychosis. Br. J. Psychiatry. 1999;174:150–153
  18. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry. 2005;57(10):1117–1127
  19. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry. 2001;50(2):71–83
  20. Dean B, Sundram S, Bradbury R, et al. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience. 2001;103(1):9–15
  21. Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry. 1991;148(2):224–230
  22. Drake RJ, Haley CJ, Akhtar S, et al. Causes and consequences of duration of untreated psychosis in schizophrenia. Br. J. Psychiatry. 2000;177:511–515
  23. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J. Clin. Psychiatry. 2000;61(Suppl 4):10–14
  24. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 2009;156(7):1029–1040
  25. Frangou S, Hadjulis M, Vourdas A. The Maudsley early onset schizophrenia study: cognitive function over a 4-year follow-up period. Schizophr. Bull. 2008;34(1):52–59
  26. Gfroerer JC, Wu L-T, Penne MA. Initiation of marijuana use: trends, patterns, and implications, DHHS Publication No. SMA 02-3711, Analytic Series A-17. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD. http://www.oas.samhsa.gov/analytic.htm2002;Available at
  27. Giuffrida A, Parsons LH, Kerr TM, et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 1999;2(4):358–363
  28. Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 2004;66(2–3):125–135
  29. Gunduz-Bruce H, Narr KL, Gueorguieva R, et al. CSF sub-compartments in relation to plasma osmolality in healthy controls and in patients with first episode schizophrenia. Psychiatry Res. 2007;155(1):57–66
  30. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biol. Psychiatry. 1996;40(11):1155–1163
  31. Hoff AL, Harris D, Faustman WO, et al. A neuropsychological study of early onset schizophrenia. Schizophr. Res. 1996;20(1–2):21–28
  32. Hollingshead AB, Redlich FC. Social Class and Mental Illness; A Community Study. New York: Wiley; 1958;
  33. Honer WG, Kopala LC, Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol. 2005;19(3):277–285
  34. Jeste DV, McAdams LA, Palmer BW, et al. Relationship of neuropsychological and MRI measures to age of onset of schizophrenia. Acta Psychiatr. Scand. 1998;98(2):156–164
  35. Kovasznay B, Fleischer J, Tanenberg-Karant M, et al. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr. Bull. 1997;23(2):195–201
  36. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009;9:59
  37. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry. 1994;51(4):273–279
  38. Loberg EM, Hugdahl K. Cannabis use and cognition in schizophrenia. Front. Hum. Neurosci. 2009;3:53
  39. Mauri MC, Volonteri LS, De Gaspari IF, et al. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin. Pract. Epidemol. Ment. Health. 2006;2:4
  40. Muller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002;35(2):57–61
  41. Muller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry. 2003;64(4):459–465
  42. Oie M, Hugdahl K. A 10–13year follow-up of changes in perception and executive attention in patients with early-onset schizophrenia: a dichotic listening study. Schizophr. Res. 2008;106(1):29–32
  43. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol. Med. 2009;39(7):1065–1076
  44. Peralta, V., Campos, M. S., De Jalon, E. G., et al., Motor behavior abnormalities in drug-naive patients with schizophrenia spectrum disorders. Mov Disord.
  45. Rabinowitz J, Bromet EJ, Lavelle J, et al. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol. Med. 1998;28(6):1411–1419
  46. Ritzler BA, Strauss JS, Vanord A, et al. Prognostic implications of various drinking patterns in psychiatric patients. Am. J. Psychiatry. 1977;134(5):546–549
  47. Robinson D, Woerner M, Schooler N. Intervention research in psychosis: issues related to clinical assessment. Schizophr. Bull. 2000;26(3):551–556
  48. Robinson DG, Woerner MG, Napolitano B, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am. J. Psychiatry. 2006;163(12):2096–2102
  49. SAMHSA . Results from the 2005 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies; 2006;
  50. Sevy S, Burdick KE, Visweswaraiah H, et al. Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr. Res. 2007;92(1–3):74–84
  51. Sevy S, Kay SR, Opler LA, et al. Significance of cocaine history in schizophrenia. J. Nerv. Ment. Dis. 1990;178(10):642–648
  52. Sevy S, Robinson DG, Holloway S, et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. 2001;104(5):367–374
  53. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970;212:11–19
  54. Strakowski SM, Tohen M, Stoll AL, et al. Comorbidity in psychosis at first hospitalization. Am. J. Psychiatry. 1993;150(5):752–757
  55. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am. J. Psychiatry. 1995;152(5):698–703
  56. Tanda G, Di Pontieri FE, Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276(5321):2048–2050
  57. Thaden E, Rhinewine JP, Lencz T, et al. Early-onset schizophrenia is associated with impaired adolescent development of attentional capacity using the identical pairs continuous performance test. Schizophr. Res. 2006;81(2–3):157–166
  58. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis. Demographic characteristics, clinical features, and family history. Arch. Gen. Psychiatry. 1982;39(2):141–147
  59. Tuulio-Henriksson A, Partonen T, Suvisaari J, et al. Age at onset and cognitive functioning in schizophrenia. Br. J. Psychiatry. 2004;185:215–219
  60. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 2004;39(1):69–72
  61. van Os J, Bak M, Hanssen M, et al. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002;156(4):319–327
  62. Veen ND, Selten JP, van der Tweel I, et al. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry. 2004;161(3):501–506
  63. Wade D, Harrigan S, Edwards J, et al. Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr. Res. 2006;81(2–3):145–150
  64. Wade D, Harrigan S, Edwards J, et al. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br. J. Psychiatry. 2006;189:229–234
  65. Weiser M, Knobler HY, Noy S, et al. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am. J. Med. Genet. 2002;114(8):949–955
  66. White T, Ho BC, Ward J, et al. Neuropsychological performance in first-episode adolescents with schizophrenia: a comparison with first-episode adults and adolescent control subjects. Biol. Psychiatry. 2006;60(5):463–471
  67. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am. J. Psychiatry. 2008;165(5):579–587
  68. Zammit S, Allebeck P, Andreasson S, et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br. Med. J. 2002;325(7374):1199

PII: S0920-9964(10)01208-9

doi: 10.1016/j.schres.2010.03.037

Schizophrenia Research
Volume 120, Issue 1 , Pages 101-107 , July 2010

Article Tools